Key takeaways
Withdrawal of Actions
Parties may withdraw actions and counterclaims before a final decision if there’s no legitimate interest in continuing according to R. 265.1 RoP, as is the case with settlements.
In this case, both the claimant and the defendant withdrew their respective action and counterclaim after reaching a settlement.
Withdrawal of Compensation Applications
Applications for compensation under R. 213.2 RoP are treated like actions and can be withdrawn under the same conditions as other actions according to R. 265 RoP.
Similar to the main action and the counterclaim, the defendants also withdrew their application for compensation after the settlement.
Partial Reimbursement of Fees
The court can deviate from the standard fee reimbursement scale in exceptional cases, such as when the proceedings have been particularly intensive according to R. 370.9 (e) RoP.
Due to the high number of applications filed and the resulting workload for the court, only 40% of the fees were reimbursed for the infringement action and counterclaim.
Fees for Compensation Applications
Applications for compensation under Rule 213.2 RoP are subject to court fees, payable by the applicant.
The court rejected the defendants’ argument that no fees are due for such applications, clarifying that the UPC operates on a fee-based system.
Notably, the term “damages” in Rule 132 RoP, concerning fees, includes compensation sought under Rule 213.2 RoP. This clarifies that the existing fee structure applies to compensation applications.
Division
LD Munich, Panel 1
UPC number
UPC CFI 2/2023; UPC CFI 298/2023
Type of proceedings
Infringement action, counterclaim for revocation, application for compensation
Parties
Claimants: 10x Genomics, Inc., President and Fellows of Harvard College
Defendants: Bruker Spatial Biology, Inc., Luxendo GmbH, Bruker Nederland B.V.
Patent
EP 4 108 782
Body of legislation / Rules
Rule 265 RoP, Rule 213.2 RoP, Rule 370 RoP, Rule 125 RoP, Rule 126 RoP, Rule 132 RoP